Synthesis, Anti-Cancer Activity, Cell Cycle Arrest, Apoptosis Induction, and Docking Study of Fused Benzo[
Humans
Apoptosis
/ drug effects
Molecular Docking Simulation
Cell Cycle Checkpoints
/ drug effects
Antineoplastic Agents
/ pharmacology
MCF-7 Cells
Breast Neoplasms
/ drug therapy
Pyrimidines
/ pharmacology
Female
Proto-Oncogene Proteins c-bcl-2
/ metabolism
Cell Proliferation
/ drug effects
Myeloid Cell Leukemia Sequence 1 Protein
/ metabolism
Bcl-2/Mcl-1 assay
NCI-assay
apoptosis
chromenopyrimidine
cytotoxicity
molecular docking
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
04 Oct 2024
04 Oct 2024
Historique:
received:
30
08
2024
revised:
16
09
2024
accepted:
26
09
2024
medline:
16
10
2024
pubmed:
16
10
2024
entrez:
16
10
2024
Statut:
epublish
Résumé
Breast cancer is the predominant form of cancer among women and ranks as the second most prevalent cancer globally, affecting both developed and less developed countries. Presently, accessible cancer treatment methods either employ recently created, secure, and efficient chemotherapeutic medications or directly target innovative pathways that cause apoptosis. One of the indirect strategies for treating this fatal illness has mostly depended on its essential role in cell cycle arrest and apoptosis induction, as well as the antagonistic interaction between the Bcl-2 and Mcl-1 proteins, in order to avert major health repercussions. We reported that newly synthesized fused chromenopyrimidines (
Identifiants
pubmed: 39407625
pii: molecules29194697
doi: 10.3390/molecules29194697
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Pyrimidines
0
Proto-Oncogene Proteins c-bcl-2
0
Myeloid Cell Leukemia Sequence 1 Protein
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Taif University, Saudi Arabia
ID : project number ( TU- DSPP- 2024- 54)